|
1) |
Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy:the first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369-75. |
2) |
Boccon-Gibod L, Djavan B, Hammerer P, et al. Management of prostate-specific antigen relapse in prostate cancer:A European consensus. Int J Clin Pract. 2004;58:382-90. |
3) |
Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-32. |
4) |
Song DY, Thompson TL, Ramakrishinan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002 60:281-7. |
5) |
Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483-9. |
6) |
Cox JD, Gallagher MJ, Hammond EH, et al. Consensus statements on radiation therapy of prostate cancer:guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology. J Clin Oncol. 1999;17:1155. |
7) |
Yokomizo A, Kawamoto H, Nihei K, et al. Randomized controlled trial to evaluate radiother-apy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical pros-tatectomy:Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 2005 Jan;35(1):34-6. |